FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to						
Section 16. Form 4 or Form 5						
obligations may continue. See						
Instruction 1(b).						

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol ACURA PHARMACEUTICALS, INC								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Jones Robert B					ACUR]) >	X Director			10% Ov	ner
(Last)	(F	irst)	(Middle)		Mook 1								>	Officer below)	(give title		Other (specify below)	
C/O ACURA PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 12/08/2016								President and CEO					
616 N NORTH COURT					12/00/2010													
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) PALATII	NE IL		60067) ×	X Form filed by One Reporting Person				n
,													Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				2. Transac Date (Month/Da	Execution Date,			Code (Ir	Transaction Disposed Of (D) (Instr. 3, 4					es For ally (D) Following (I) (: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	t (A) or P		Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date, Transaction		n of E		Expiration	5. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	re es ally eg d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	le V	(A)	(D)	Date Exercisable		xpiration vate	Title	or Nu of	mber ares					
Stock Options	\$0.915 ⁽¹⁾	12/08/2016		A		47,000		(2)	1	2/07/2026	Commor Stock	47	,000	(3)	47,000)	D	

Explanation of Responses:

- 1. Exercise price is closing price of Issuer's common stock on December 8, 2016.
- 2. one-twenty-fourth of shares underlying options vest and are exercisable on the last day of each month commencing December 31, 2016 and ending on November 30, 2018. Option vesting and exercisability is accelerated upon a qualifying change of control and on termination of employment for certain reasons.
- 3. Not Applicable.

Remarks:

/s/ Robert B. Jones

12/09/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.